CStone Pharmaceuticals-B (02616.HK): Today announced that its Investigational New Drug (IND) application for the combination therapy of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) for advanced solid tumors has been approved by the National Medical Products Administration (NMPA) of China.